COMMUNIQUÉS West-GlobeNewswire

Codexis to Report Second Quarter 2026 Financial Results on August 11
28/07/2026
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]
HealthBegins Launches Online Learning Platform to Scale ‘Upstreamist’ Movement with Expert-Led Instruction and Resources
28/07/2026
HealthBegins Academy combines expert instruction, applied frameworks and flexible learning formats to turn health equity strategies into sustainable, scalable practices PASADENA, Calif., July 28, 2026 (GLOBE NEWSWIRE [...]
AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars
28/07/2026
Commercial long-term deal with a large pharmaceutical company pursuing manufacturing and commercial regulatory approvals in major markets Customer commits to AGC Biologics’ new site in Yokohama for five commercial [...]
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
28/07/2026
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care [...]
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
28/07/2026
New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- [...]
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
28/07/2026
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook [...]
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
28/07/2026
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
28/07/2026
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July 28, [...]
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
28/07/2026
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
28/07/2026
Validates OneMedNet’s Position as Premier Supplier of High-Quality Healthcare Data for Advanced AI Training. MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company [...]
Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
28/07/2026
The expansion marks Dentsply Sirona's sixth dealer network enhancement announced in 2026, further advancing its strategy to broaden access to digital dentistry solutions through trusted distribution partners CHARLOTTE, [...]
Cato Healthcare Supply Strengthens Executive Leadership Team
28/07/2026
DALLAS, July 28, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, the healthcare industry's leading revenue preservation and off-contract procurement platform, today announced the promotion and appointment of four [...]
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
28/07/2026
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand platform adoption [...]
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
28/07/2026
Filmmakers across more than 50 countries submitted work on loss and healing, signaling cinema's growing power as a shared language for grief. New York, NY, July 28, 2026 (GLOBE NEWSWIRE) -- Grief Fest™ , the first [...]
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
28/07/2026
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission [...]
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
28/07/2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review [...]
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
28/07/2026
Analysis projects national average cost savings of ~$24,000 per episode alongside improved ventilator weaning outcomes EXTON, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced results from a new [...]
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
28/07/2026
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28/07/2026
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in [...]

Pages